KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Interest & Investment Income (2016 - 2020)

Supernus Pharmaceuticals has reported Interest & Investment Income over the past 10 years, most recently at $3.3 million for Q3 2020.

  • Quarterly Interest & Investment Income fell 41.32% to $3.3 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $18.4 million through Sep 2020, down 8.81% year-over-year, with the annual reading at $13.8 million for FY2018, 383.34% up from the prior year.
  • Interest & Investment Income was $3.3 million for Q3 2020 at Supernus Pharmaceuticals, down from $4.2 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $5.6 million in Q3 2019 and troughed at $327000.0 in Q1 2016.
  • The 5-year median for Interest & Investment Income is $1.2 million (2018), against an average of $2.4 million.
  • Year-over-year, Interest & Investment Income soared 458.54% in 2018 and then crashed 41.32% in 2020.
  • A 5-year view of Interest & Investment Income shows it stood at $396000.0 in 2016, then skyrocketed by 117.68% to $862000.0 in 2017, then soared by 423.43% to $4.5 million in 2018, then grew by 23.2% to $5.6 million in 2019, then crashed by 41.32% to $3.3 million in 2020.
  • Per Business Quant, the three most recent readings for SUPN's Interest & Investment Income are $3.3 million (Q3 2020), $4.2 million (Q2 2020), and $5.6 million (Q3 2019).